<DOC>
	<DOCNO>NCT01328236</DOCNO>
	<brief_summary>Bortezomib/Liposomal doxorubicin ( V-DD ) prefer bortezomib single agent salvage therapy Multiple Myeloma ( MM ) . The present study design assessment efficacy safety study Bortezomib combination Liposomal Doxorubicin Dexamethasone treatment Plasma Cell Leukemia ( PCL ) . Primary study endpoint overall response rate ( sCR+CR+VGPR+PR ) . Secondary endpoint rate complete response ( sCR+CR ) , partial remission rate ( VGPR + PR ) , duration response ( DOR ) , overall survival ( OS ) .</brief_summary>
	<brief_title>Bortezomib Combination With Liposomal Doxorubicin Dexamethasone Treat Plasma Cell Leukemia</brief_title>
	<detailed_description>Patient Plasma Cell Leukemia ( PCL ) multiple myeloma ( MM ) ; KPS ≥ 60scores</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Leukemia , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patients confirm relapsed refractory PCL previously untreated never receive treatment Bortezomib KPS ≥ 60 Adequate liver renal function within 2 week Screening : Bilirubin ≤ 1.5 × upper limit normal ( ULN ) Alanine aminotransferase ( ALT ) ≤ 2.5 × upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) ≤ 2.5 × upper limit normal ( ULN ) Cardiac function &gt; Ⅲ grade ejection fraction &gt; 45 % Signed informed consent prior initiation studyrelated procedure consider standard care take Bortezomib KPS ≤ 60 score mental illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Bortezomib</keyword>
	<keyword>PCL</keyword>
</DOC>